Cytokinetics Inc
$ 69.27
3.28%
11 Jun - close price
- Market Cap 9,404,829,000 USD
- Current Price $ 69.27
- High / Low $ 70.55 / 67.45
- Stock P/E N/A
- Book Value -6.65
- EPS -6.85
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -5.72 %
- 52 Week High 80.20
- 52 Week Low 31.99
About
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$104.70
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-27 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -1.67 | -1.5 | -1.54 | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 |
| Estimated EPS | -1.65 | -1.56 | -1.57 | -1.36 | -1.36 | -1.174 | -1.24 | -0.91 | -1.17 | -0.97 | -0.76 | -1.24 |
| Surprise | -0.02 | 0.06 | 0.03 | 0.24 | 0 | -0.086 | -0.12 | -0.4 | -0.16 | -0.41 | -0.59 | -0.1 |
| Surprise Percentage | -1.2121% | 3.8462% | 1.9108% | 17.6471% | 0% | -7.3254% | -9.6774% | -43.956% | -13.6752% | -42.268% | -77.6316% | -8.0645% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.64 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYTK
2026-06-12 09:40:10
Monashee Investment Management LLC reduced its stake in Cytokinetics, Incorporated by 25% in the fourth quarter, selling 25,000 shares and retaining 75,000 shares valued at $4.77 million. Despite this insider selling and some other insider transactions, analysts maintain a "Moderate Buy" rating with an average target price of $99.30 for CYTK, which reported strong revenue growth in its latest quarter. The biopharmaceutical company focuses on novel small-molecule therapeutics for muscle function, with its lead program, omecamtiv mecarbil, targeting heart failure.
2026-06-12 03:40:10
Cytokinetics (CYTK) has launched MYQORZO in Germany, marking its first European commercial entry for treating obstructive hypertrophic cardiomyopathy. This launch, backed by positive Phase 3 data, expands the drug's market and provides an early validation for Cytokinetics' use of recently raised capital. While modestly de-risking the company's investment narrative, challenges remain around scaling sales to support its growing expenses and expanded share count, despite projections of significant revenue and earnings growth by 2029.
2026-06-10 09:09:01
Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK), sold 3,500 shares of the company on June 9, 2026. Following this transaction, Malik now owns 153,902 shares. The stock is currently trading at $67.98, and with a GuruFocus Value of $248.81, it is considered a "Possible Value Trap, Think Twice."
2026-06-09 22:09:01
This article details recent insider trading activity at CYTOKINETICS INC (CYTK) by EVP Research & Development, Malik Fady Ibraham, as reported in a Form 4 SEC filing. The insider sold 3,500 shares of common stock for approximately $238,000, following the exercise of non-qualified stock options. After these transactions, Malik Fady Ibraham retains 157,402 shares of common stock and 44,386 non-qualified stock options.
2026-06-09 01:09:58
Cytokinetics (CYTK) is under renewed investor focus following the commercial launch of MYQORZO in Germany for obstructive hypertrophic cardiomyopathy, a milestone expected to impact its market valuation. Despite recent short-term share price weakness, the company has shown strong long-term momentum with a 1-year total shareholder return of 115.76%. Analysts currently value CYTK at $92.94, suggesting it is 23.1% undervalued, driven by expectations of rapid top-line expansion and profitability improvements, though risks like trial disappointments or slower commercial uptake remain.
2026-06-08 11:09:36
Cytokinetics, Inc. has announced its annual Corporate Giving Program, which invites non-profit organizations to submit proposals for charitable donations up to $20,000. The program aims to support equitable healthcare initiatives for cardiovascular disease, science education, and essential services for local and at-risk communities. Applications are open until August 3, 2026.
